Catalent Pharma Solutions and GlaxoSmithKline (GSK) have extended their contract under which Catalent will continue to supply GSK with its trade requirements of Lovaza omega-3 acid ethyl esters in soft gelatin capsules. Lovaza is an omega-3 prescription medication derived from fish oil approved by the FDA to reduce very high triglycerides. The Lovaza softgels are manufactured in Catalent’s St. Petersburg, FL facility, which is part of Catalent’s Oral Technologies segment.

“We value our long-term partnership with GSK and look forward to continuing that relationship,” said Dr. Aris Gennadios, Catalent’s vice president and general manager, Pharmaceutical Softgels.